Treatment of type II gastric carcinoid tumors with somatostatin analogues.
Tomassetti
P
P
Department of Internal Medicine and Gastroenterology, University of Bologna, Italy.
Migliori
M
M
Caletti
G C
GC
Fusaroli
P
P
Corinaldesi
R
R
Gullo
L
L
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005755:Gastrins / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications; D015282:Octreotide / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000209:etiology; D015043:Zollinger-Ellison Syndrome / Q000150:complications
D000970:Antineoplastic Agents; D005755:Gastrins; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide